AVN 71.20 Increased By ▲ 2.70 (3.94%)
BOP 9.05 Increased By ▲ 0.20 (2.26%)
CHCC 133.50 Increased By ▲ 3.50 (2.69%)
DCL 9.25 Increased By ▲ 0.10 (1.09%)
DGKC 106.21 Increased By ▲ 2.05 (1.97%)
EFERT 60.95 Increased By ▲ 0.10 (0.16%)
EPCL 45.42 Increased By ▲ 1.22 (2.76%)
FCCL 21.04 Increased By ▲ 0.24 (1.15%)
FFL 15.15 Increased By ▲ 0.55 (3.77%)
HASCOL 14.48 Increased By ▲ 0.20 (1.4%)
HBL 130.44 Increased By ▲ 0.14 (0.11%)
HUBC 79.25 Increased By ▲ 0.35 (0.44%)
HUMNL 6.20 Decreased By ▼ -0.05 (-0.8%)
JSCL 27.80 Increased By ▲ 1.60 (6.11%)
KAPCO 28.23 Increased By ▲ 0.03 (0.11%)
KEL 3.68 Increased By ▲ 0.01 (0.27%)
LOTCHEM 13.05 Increased By ▲ 0.20 (1.56%)
MLCF 40.27 Increased By ▲ 1.03 (2.62%)
OGDC 100.13 Increased By ▲ 2.13 (2.17%)
PAEL 33.80 Increased By ▲ 1.11 (3.4%)
PIBTL 12.66 Increased By ▲ 0.36 (2.93%)
PIOC 92.77 Increased By ▲ 1.61 (1.77%)
POWER 9.78 Increased By ▲ 0.24 (2.52%)
PPL 92.51 Increased By ▲ 2.72 (3.03%)
PSO 199.15 Increased By ▲ 2.35 (1.19%)
SNGP 44.00 Increased By ▲ 1.80 (4.27%)
STPL 15.36 Increased By ▲ 0.96 (6.67%)
TRG 69.07 Increased By ▲ 3.87 (5.94%)
UNITY 26.86 Increased By ▲ 1.54 (6.08%)
WTL 1.05 No Change ▼ 0.00 (0%)
BR100 4,335 Increased By ▲ 68.12 (1.6%)
BR30 22,012 Increased By ▲ 442.39 (2.05%)
KSE100 41,665 Increased By ▲ 596.45 (1.45%)
KSE30 17,533 Increased By ▲ 251.98 (1.46%)
World

India declines proposal to test Sputnik-V COVID-19 vaccine in large study

  • India's move comes as a setback for Russia's plan to roll-out the vaccine even before full trials show how well it works.
  • India is expected to overtake the United States over the next several weeks as the country with the world's largest number of cases.
08 Oct 2020

India's drug regulator has knocked back a proposal from Dr Reddy's Laboratories Ltd to conduct a large study in the country to evaluate Russia's Sputnik-V COVID-19 vaccine and has asked it to first test the vaccine in a smaller trial.

The recommendations by an expert panel of the Central Drugs Standard Control Organisation (CDSCO) noted that safety and immunogenicity data from early-stage studies being conducted overseas is small, with no inputs available on Indian participants.

India's move comes as a setback for Russia's plan to roll-out the vaccine even before full trials show how well it works, while pushing back its efforts to win approval for the vaccine in the country that leads the world on average number of new infections.

India is expected to overtake the United States over the next several weeks as the country with the world's largest number of cases.

The Russian Direct Investment Fund (RDIF), which is marketing the Sputnik V, and Dr. Reddy's Laboratories last month announced their partnership to run clinical trials and distribute the vaccine in India.

Russia was the first country to grant regulatory approval for a novel coronavirus vaccine, and did so before large-scale trials were complete, stirring concerns among scientists and doctors about the safety and efficacy of the shot.

RDIF and Dr. Reddy's did not immediately reply to Reuters' requests for comment outside business hours.